MIRA
MIRA Pharmaceuticals, Inc.
Drug Manufacturers - General
Market Cap$40M
5Y Perf.-84.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MIRA vs JAZZ
Revenue, margins, valuation, and 5-year total return — side by side.
JAZZ
Jazz Pharmaceuticals plc
Biotechnology
Market Cap$14.34B
5Y Perf.+59.4%
MIRA vs JAZZ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MIRA | JAZZ |
|---|---|---|
| Industry | Drug Manufacturers - General | Biotechnology |
| Market Cap | $40M | $14.34B |
| Revenue (TTM) | $0.00 | $4.44B |
| Net Income (TTM) | $-28M | $29M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 13.9% |
| Forward P/E | — | 9.5x |
| Total Debt | $0.00 | $5.42B |
| Cash & Equiv. | $3M | $1.39B |
MIRA vs JAZZ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MIRA
JAZZ
| Stock | Aug 23 | May 26 | Return |
|---|---|---|---|
| MIRA Pharmaceutical… (MIRA) | 100 | 15.9 | -84.1% |
| Jazz Pharmaceutical… (JAZZ) | 100 | 159.4 | +59.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MIRA vs JAZZ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JAZZ leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. MIRA Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
MIRA
MIRA Pharmaceuticals, Inc.
The Growth Play
MIRA is the clearest fit if your priority is growth exposure.
- EPS growth 21.5%
- 103.2% revenue growth vs JAZZ's 4.9%
Best for: growth exposure
JAZZ
Jazz Pharmaceuticals plc
The Income Pick
JAZZ carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.65
- 58.3% 10Y total return vs MIRA's -84.4%
- Lower volatility, beta 0.65, current ratio 1.86x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MIRA | 103.2% revenue growth vs JAZZ's 4.9% |
| Quality / Margins | JAZZ | 0.7% margin vs MIRA's -5.7% |
| Stability / Safety | JAZZ | Beta 0.65 vs MIRA's 1.72 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | JAZZ | +105.6% vs MIRA's -16.7% |
| Efficiency (ROA) | JAZZ | 0.3% ROA vs MIRA's -372.3% |
MIRA vs JAZZ — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
MIRA vs JAZZ — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJAZZLAGGINGMIRA
MIRAMIRA Pharmaceuticals,…
0leads
JAZZJazz Pharmaceuticals …
5leads
6 Total Categories
CATEGORYLEADERvs MIRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JAZZ1/1
Valuation MetricsMultiples, price ratios, and targets
JAZZ2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JAZZ5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
JAZZ6/6
Risk & VolatilityBeta, volatility, and downside exposure
JAZZ2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
JAZZ leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
JAZZ and MIRA operate at a comparable scale, with $4.4B and $0 in trailing revenue.
| Metric | MIRAMIRA Pharmaceutic… | JAZZJazz Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $4.4B |
| EBITDAEarnings before interest/tax | -$7M | $994M |
| Net IncomeAfter-tax profit | -$28M | $29M |
| Free Cash FlowCash after capex | -$5M | $1.2B |
| Gross MarginGross profit ÷ Revenue | — | +66.9% |
| Operating MarginEBIT ÷ Revenue | — | +13.9% |
| Net MarginNet income ÷ Revenue | — | +0.7% |
| FCF MarginFCF ÷ Revenue | — | +28.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +19.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -7.4% | +3.9% |
JAZZ leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
JAZZ leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | MIRAMIRA Pharmaceutic… | JAZZJazz Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $40M | $14.3B |
| Enterprise ValueMkt cap + debt − cash | $37M | $18.4B |
| Trailing P/EPrice ÷ TTM EPS | -1.96x | -39.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 23.97x |
| Price / SalesMarket cap ÷ Revenue | — | 3.36x |
| Price / BookPrice ÷ Book value/share | 7.02x | 3.23x |
| Price / FCFMarket cap ÷ FCF | — | 11.06x |
JAZZ leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
JAZZ leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
JAZZ delivers a 0.7% return on equity — every $100 of shareholder capital generates $1 in annual profit, vs $-4 for MIRA. On the Piotroski fundamental quality scale (0–9), JAZZ scores 5/9 vs MIRA's 3/9, reflecting solid financial health.
| Metric | MIRAMIRA Pharmaceutic… | JAZZJazz Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | -3.8% | +0.7% |
| ROA (TTM)Return on assets | -3.7% | +0.3% |
| ROICReturn on invested capital | — | +2.1% |
| ROCEReturn on capital employed | -2.4% | +2.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | 1.26x |
| Net DebtTotal debt minus cash | -$3M | $4.0B |
| Cash & Equiv.Liquid assets | $3M | $1.4B |
| Total DebtShort + long-term debt | $0 | $5.4B |
| Interest CoverageEBIT ÷ Interest expense | -48.40x | -3.72x |
JAZZ leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
JAZZ leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JAZZ five years ago would be worth $13,224 today (with dividends reinvested), compared to $1,558 for MIRA. Over the past 12 months, JAZZ leads with a +105.6% total return vs MIRA's -16.7%. The 3-year compound annual growth rate (CAGR) favors JAZZ at 18.1% vs MIRA's -46.2% — a key indicator of consistent wealth creation.
| Metric | MIRAMIRA Pharmaceutic… | JAZZJazz Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | -32.9% | +32.0% |
| 1-Year ReturnPast 12 months | -16.7% | +105.6% |
| 3-Year ReturnCumulative with dividends | -84.4% | +64.8% |
| 5-Year ReturnCumulative with dividends | -84.4% | +32.2% |
| 10-Year ReturnCumulative with dividends | -84.4% | +58.3% |
| CAGR (3Y)Annualised 3-year return | -46.2% | +18.1% |
JAZZ leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
JAZZ leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JAZZ is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than MIRA's 1.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JAZZ currently trades 99.2% from its 52-week high vs MIRA's 40.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MIRAMIRA Pharmaceutic… | JAZZJazz Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.72x | 0.65x |
| 52-Week HighHighest price in past year | $2.45 | $230.40 |
| 52-Week LowLowest price in past year | $0.90 | $97.50 |
| % of 52W HighCurrent price vs 52-week peak | +40.8% | +99.2% |
| RSI (14)Momentum oscillator 0–100 | 44.8 | 67.7 |
| Avg Volume (50D)Average daily shares traded | 158K | 956K |
JAZZ leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MIRAMIRA Pharmaceutic… | JAZZJazz Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $216.14 |
| # AnalystsCovering analysts | — | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
JAZZ leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallJazz Pharmaceuticals plc (JAZZ)Leads 5 of 6 categories
Loading custom metrics...
MIRA vs JAZZ: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MIRA or JAZZ a better buy right now?
Analysts rate Jazz Pharmaceuticals plc (JAZZ) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MIRA or JAZZ?
Over the past 5 years, Jazz Pharmaceuticals plc (JAZZ) delivered a total return of +32.
2%, compared to -84. 4% for MIRA Pharmaceuticals, Inc. (MIRA). Over 10 years, the gap is even starker: JAZZ returned +58. 3% versus MIRA's -84. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MIRA or JAZZ?
By beta (market sensitivity over 5 years), Jazz Pharmaceuticals plc (JAZZ) is the lower-risk stock at 0.
65β versus MIRA Pharmaceuticals, Inc. 's 1. 72β — meaning MIRA is approximately 166% more volatile than JAZZ relative to the S&P 500.
04Which is growing faster — MIRA or JAZZ?
On earnings-per-share growth, the picture is similar: MIRA Pharmaceuticals, Inc.
grew EPS 21. 5% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MIRA or JAZZ?
MIRA Pharmaceuticals, Inc.
(MIRA) is the more profitable company, earning 0. 0% net margin versus -8. 3% for Jazz Pharmaceuticals plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JAZZ leads at 5. 3% versus 0. 0% for MIRA. At the gross margin level — before operating expenses — JAZZ leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MIRA or JAZZ?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MIRA or JAZZ better for a retirement portfolio?
For long-horizon retirement investors, Jazz Pharmaceuticals plc (JAZZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
65)). MIRA Pharmaceuticals, Inc. (MIRA) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JAZZ: +58. 3%, MIRA: -84. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MIRA and JAZZ?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.